<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-10908-2014080 - 2S2UI</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Act now for affordable HIV treatment in Egypt, Morocco and Tunisia</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">This project aims to facilitate generic competition for key ARVs, which will lead to significantly lower prices. These price reductions will then enable Morocco, Tunisia and Egypt to purchase more medicines and treat more of the patients still in need of ART. This projectwill also help ensure that these countries can afford to procure the highest-quality, WHO-recommended regimens.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">This project will focus on three target countries from MENA region: Morocco, Tunisia and Egypt. Providing these countries with access to affordable, generic ARVs is critical to addressing the large unmet need for ART. Lack of generic availability and high branded prices for key ARVs have directly translated to restricted ART coverage and/or an inability to provide the best possible regimens for patients in the three target countries.  By addressing the legal and intellectual property barriers to generic market entry in the three target countries, this intervention aims to facilitate generic competition for key ARVs, which will lead to significantly lower prices. ITPC-MENA will organize national trainings on IP and access to medicines in each country to create knowledge and strengthen capacities of civil society groups. The project aims for national IP laws that are public health friendly and include all TRIPS safeguards.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">While the HIV epidemic in the Middle East and North Africa (MENA) is considered among the fastest growing epidemics in the world, the region registers the lowest rate of coverage of ART with less than one in eight people eligible for ART receiving it by end of 2012. This project will focus on three target countries from MENA region: Morocco, Tunisia and Egypt, which combined represent 12.000 people living with HIV. In all of these countries, HIV infections are more concentrated in stigmatized and vulnerable populations such as sex workers, injecting drug users, and men who have sex with men. Providing these countries with access to affordable, generic ARVs is critical to addressing the large unmet need for ART.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN"></narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <participating-org role="4" type="23">
   <narrative xml:lang="EN">ITPC-MENA</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-12-31" type="1"></activity-date>
  <activity-date iso-date="2018-12-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="EG" percentage="33.333333333333336"></recipient-country>
  <recipient-country code="MA" percentage="33.333333333333336"></recipient-country>
  <recipient-country code="TN" percentage="33.333333333333336"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Act now for affordable HIV treatment in Egypt, Morocco and Tunisia STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2014-12-31"></period-start>
   <period-end iso-date="2018-12-31"></period-end>
   <value currency="EUR" value-date="2014-12-31">120000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">32000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">32000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-03-27"></transaction-date>
   <value currency="EUR" value-date="2016-03-27">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-03-27"></transaction-date>
   <value currency="EUR" value-date="2016-03-27">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-09-27"></transaction-date>
   <value currency="EUR" value-date="2016-09-27">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-09-27"></transaction-date>
   <value currency="EUR" value-date="2016-09-27">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-03-26"></transaction-date>
   <value currency="EUR" value-date="2017-03-26">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-03-27"></transaction-date>
   <value currency="EUR" value-date="2017-03-27">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-10-25"></transaction-date>
   <value currency="EUR" value-date="2018-10-25">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-10-25"></transaction-date>
   <value currency="EUR" value-date="2018-10-25">16000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-07-22"></transaction-date>
   <value currency="EUR" value-date="2019-07-22">24000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-07-23"></transaction-date>
   <value currency="EUR" value-date="2019-07-23">24000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014080</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ITPC-MENA</narrative>
   </receiver-org>
  </transaction>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">Local advocates, journalists and decision makers have straightened capacity to advocate for the use of TRIPS flexibilities</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">15 persons trained on IP and access to medicines (including advocates, journalists, decision makers) in each target country</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of national trainings organized</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">Participation of civil society and consumer groups is increased in the patent system</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Access strategy will be developed and implemented</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of countries for which formal government requests are made to initiate negotiations with patent-holders</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">TRIPS Flexibilities adopted at country level</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Opposition or invalidation of identified abusive patents</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of amendments to IP law drafted</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of compulsory licenses demands initiated in focus countries,</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of patent invalidations/oppositions requests initiated with the patent offices in focus countries</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">Wide support on FTAs is created to lead advocacy in each of the 3 countries</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Organizations mobilized calling for the use of TRIPS flexibilities and FTA education and advocacy campaign</narrative>
   </description>
   <indicator measure="2">
    <title>
     <narrative xml:lang="EN">Creation of cross country coalition in advocacy to resist EU pressure</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="100"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">A debate on the importance of the use of TRIPS flexibilities in the 3 focus countries is initiated</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Policy and cross-disciplinary dialogue and educational meetings with decision-makers.</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of meetings, conferences, educational sessions conducted in each country</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">Public opinion is aware of the negative impact of TRIPSplus provisions</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Policy briefs, meetings, press articles and media coverage on the EU FTA, Number of articles, media coverage, social media reach</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of anti FTA campaigns organized</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">Importance of TRIPS flexibilities and their impact on access to medicines are widely known and understood across 3 countries</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Research and analysis of national patent laws in 3 countries conducted and IP and ARV access guides produced and distributed widely</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Number of IP laws analyzed</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">The link between patent protection and lack of access of specific medicines is documented and widely understood at country level</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Research to identify priority medicines for PLWHIV</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Short list of priority ARVs and key medicines needed by PLWHIV developed, augmented and widely disseminated</narrative>
    </title>
    <period>
     <period-start iso-date="2016-01-01"></period-start>
     <period-end iso-date="2016-12-31"></period-end>
     <actual value="0"></actual>
    </period>
    <period>
     <period-start iso-date="2014-12-31"></period-start>
     <period-end iso-date="2017-12-30"></period-end>
     <target value="3"></target>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
